Espagnolle Nicolas, Hebraud Benjamin, Descamps Jean-Gérard, Gadelorge Mélanie, Joubert Marie-Véronique, Ferreira Laura Do Souto, Roussel Murielle, Huynh Anne, Sensébé Luc, Casteilla Louis, Attal Michel, Avet-Loiseau Hervé, Deschaseaux Frederic, Bourin Philippe, Corre Jill
STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France.
EFS Occitanie, 31042 Toulouse, France.
Stem Cells Int. 2020 Mar 5;2020:4173578. doi: 10.1155/2020/4173578. eCollection 2020.
Multiple myeloma (MM) is an incurable B cell neoplasia characterized by the accumulation of tumor plasma cells within the bone marrow (BM). As a consequence, bone osteolytic lesions develop in 80% of patients and remain even after complete disease remission. We and others had demonstrated that BM-derived mesenchymal stromal cells (MSCs) are abnormal in MM and thus cannot be used for autologous treatment to repair bone damage. Adipose stromal cells (ASCs) represent an interesting alternative to MSCs for cellular therapy. Thus, in this study, we wondered whether they could be a good candidate in repairing MM bone lesions. For the first time, we present a transcriptomic, phenotypic, and functional comparison of ASCs from MM patients and healthy donors (HDs) relying on their autologous MSC counterparts. In contrast to MM MSCs, MM ASCs did not exhibit major abnormalities. However, the changes observed in MM ASCs and the supportive property of ASCs on MM cells question their putative and safety uses at an autologous or allogenic level.
多发性骨髓瘤（MM）是一种无法治愈的B细胞肿瘤，其特征是肿瘤浆细胞在骨髓（BM）中积聚。因此，80%的患者会出现骨溶解性病变，即使在疾病完全缓解后仍会存在。我们和其他人已经证明，骨髓来源的间充质基质细胞（MSC）在MM中是异常的，因此不能用于自体治疗来修复骨损伤。脂肪基质细胞（ASC）是用于细胞治疗的一种有趣的替代MSC的细胞。因此，在本研究中，我们想知道它们是否可能是修复MM骨病变的良好候选者。我们首次基于MM患者和健康供体（HD）的自体MSC，对其ASC进行了转录组学、表型和功能比较。与MM MSC不同，MM ASC没有表现出主要异常。然而，在MM ASC中观察到的变化以及ASC对MM细胞的支持特性，质疑了它们在自体或异体水平上的假定用途和安全性。
